Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients.


:Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcutaneously in concentrations between 1% and 3%. The intravenous route was preferred in patients with indwelling catheters or those susceptible to inflammatory skin reactions at the infusion site. After initial dose adjustment, lasting 2-3 days, the morphine amounts infused by PCA reached a median of 93 mg day(-1) (range 12-464 mg day(-1)). The median was 28% lower than the median dose administered orally. A total of 84% of patients utilized the option of bolus self-administration. The median percentage administered via the bolus mode amounted to 5.3% of the total requirements. During the course of treatment, morphine requirements increased by a median of 2.3 mg day(-1) (range -29 +52 mg day(-1)). Most patients were treated continuously in the home care setting until death, the median duration being 27 days (range 1-437 days). The terminal morphine demands reached a median of 188 mg day(-1) (range 15-1008 mg day(-1)). PCA turned out to be safe and effective, attaining excellent results in 95 (66%) patients and satisfactory pain relief in 43 (30%). PCA proved to be insufficient in five (4%) cases. Side-effects were mild: constipation, fatigue, nausea and local inflammatory skin reactions occurred in 9%. Thus, with support from an experienced mobile nursing team, PCA can be safely administered in the terminal domiciliary care of tumour patients. PCA is superior to oral analgesia, especially in the treatment of severe oscillating pain. PCA provides adequate pain control in about 96% of patients who are poorly responsive to oral opioids.


Cancer Treat Rev


Cancer treatment reviews


Meuret G,Jocham H




Has Abstract


1996-01-01 00:00:00










22 Suppl A


  • A preclinical and clinical review of aflibercept for the management of cancer.

    abstract::Aflibercept, also known as vascular endothelial growth factor (VEGF)-Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only all forms of VEGF-A, but also VEGF-B and placental growth factor. It inhibits VEGF-induced angiogenesis in preclinical models. In t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Gaya A,Tse V

    更新日期:2012-08-01 00:00:00

  • Targeting uPA/uPAR in prostate cancer.

    abstract::Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP met...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Li Y,Cozzi PJ

    更新日期:2007-10-01 00:00:00

  • Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.

    abstract::Epithelial ovarian cancer (EOC) is the most common gynaecological malignancy in the Western world and a leading cause of death. Patients with relapsed EOC are incurable and therefore the toxicity of palliative chemotherapy and effects on health-related Quality of Life are important factors. Several newer cytotoxic age...

    journal_title:Cancer treatment reviews

    pub_type: 临床试验,杂志文章,随机对照试验,评审


    authors: Stebbing J,Gaya A

    更新日期:2002-04-01 00:00:00

  • Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

    abstract::Despite improvements in the management of patients with early breast cancer, the prognosis for women with locally advanced breast cancer (LABC) remains poor. The potential goals of neoadjuvant treatment for this disease include down-sizing tumours to allow breast conservation as well as the possibility of improving su...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Freedman OC,Verma S,Clemons MJ

    更新日期:2005-02-01 00:00:00

  • Radiotherapy-induced ear toxicity.

    abstract::Despite their particular functional consequences, radiotherapy-induced ear injuries remain under-evaluated and under-reported. These reactions may have acute or late character, may affect all structures of the hearing organ, and result in conductive, sensorineural or mixed hearing loss. Up to 40% of patients have acut...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Jereczek-Fossa BA,Zarowski A,Milani F,Orecchia R

    更新日期:2003-10-01 00:00:00

  • Alternative formulations of paclitaxel.

    abstract::Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Terwogt JM,Nuijen B,Huinink WW,Beijnen JH

    更新日期:1997-03-01 00:00:00

  • Intraperitoneal chemotherapy in ovarian cancer.

    abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Hofstra LS,de Vries EG,Mulder NH,Willemse PH

    更新日期:2000-04-01 00:00:00

  • Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

    abstract::Tissue hypoxia occurs where there is an imbalance between oxygen supply and consumption. Hypoxia occurs in solid tumours as a result of an inadequate supply of oxygen, due to exponential cellular proliferation and an inefficient vascular supply. It is an adverse prognostic indicator in cancer as it is associated with ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Shannon AM,Bouchier-Hayes DJ,Condron CM,Toomey D

    更新日期:2003-08-01 00:00:00

  • To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review.

    abstract:BACKGROUND:The association between alcohol intake and breast cancer recurrence or development of second primary breast cancer in the survivor population is unclear. The aim of this systematic review was to evaluate the existing evidence to assess the extent to which alcohol consumption is associated with breast cancer ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Simapivapan P,Boltong A,Hodge A

    更新日期:2016-11-01 00:00:00

  • Prevention of chemotherapy and radiation toxicity with glutamine.

    abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Savarese DM,Savy G,Vahdat L,Wischmeyer PE,Corey B

    更新日期:2003-12-01 00:00:00

  • Is there a role for a specialized follow-up clinic for survivors of pediatric cancer?

    abstract::Due to advances in chemotherapy and supportive care, greater than 70% of patients with childhood cancer will survive 5 years. However, there are long-term physiological and psychological sequelae of these treatments that may not manifest until pediatric survivors are into adulthood. Various studies done in the long-te...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Prasad PK,Bowles T,Friedman DL

    更新日期:2010-06-01 00:00:00

  • Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

    abstract::Hepatocellular carcinoma (HCC) is one of the most frequent and deadliest cancers worldwide. Liver transplantation, surgical resection or local ablation offer the best survival advantages but most patients either present when the tumor is in an advanced stage or the degree of underlying liver disease precludes these op...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Meza-Junco J,Montano-Loza AJ,Liu DM,Sawyer MB,Bain VG,Ma M,Owen R

    更新日期:2012-02-01 00:00:00

  • Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Solinas C,Ceppi M,Lambertini M,Scartozzi M,Buisseret L,Garaud S,Fumagalli D,de Azambuja E,Salgado R,Sotiriou C,Willard-Gallo K,Ignatiadis M

    更新日期:2017-06-01 00:00:00

  • Preoperative chemotherapy for non-small cell lung cancer.

    abstract::Surgery has been considered the standard of care in patients with early-stage non-small cell lung cancer (NSCLC), as well as in some cases of stage III, for a long time. Poor survival after complete resection has led to the search for new therapeutic strategies such as combining anticancer treatments. However, at the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Depierre A,Westeel V,Jacoulet P

    更新日期:2001-04-01 00:00:00

  • Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

    abstract::Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

    更新日期:1989-06-01 00:00:00

  • Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.

    abstract:PURPOSE:To conduct a systematic review and meta-analysis of all phase III randomized controlled trials comparing efficacy of early versus late first-line or initial treatments for cancer. METHODS:A comprehensive literature search of MEDLINE and Cochrane library databases was performed (1966-2008). Data was extracted a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Mhaskar AR,Quinn G,Vadaparampil S,Djulbegovic B,Gwede CK,Kumar A

    更新日期:2010-12-01 00:00:00

  • Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

    abstract::Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line treatment, and sunitinib malate is administered second-line for patients who are intolerant or progress on imatinib. Imatinib has recent...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Joensuu H,Trent JC,Reichardt P

    更新日期:2011-02-01 00:00:00

  • Beyond BRCA: new hereditary breast cancer susceptibility genes.

    abstract::Approximately 5-10% of breast cancer cases might be inheritable, up to 30% of which are due to BRCA1/2 mutations. During the past few years and thanks to technology evolution, we have been witnesses of an intensive search of additional genes with similar characteristics, under the premise that successful gene discover...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Economopoulou P,Dimitriadis G,Psyrri A

    更新日期:2015-01-01 00:00:00

  • Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.

    abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析


    authors: Marchetti C,Fagotti A,Tombolini V,Scambia G,De Felice F

    更新日期:2020-02-01 00:00:00

  • Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.

    abstract::In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician's therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently considered as potential an...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Soultati A,Mountzios G,Avgerinou C,Papaxoinis G,Pectasides D,Dimopoulos MA,Papadimitriou C

    更新日期:2012-08-01 00:00:00

  • Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.

    abstract::The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Skrzypski M,Jassem J

    更新日期:2018-05-01 00:00:00

  • Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.

    abstract::Peptide receptor radionuclide therapy (PRRT) is an important therapeutic option for somatostatin receptor (SSTR) positive metastatic and/or inoperable neuroendocrine tumours (NETs). However, in patients with poorly controlled carcinoid syndrome, it may lead to an acute flare of carcinoid symptoms or even carcinoid cri...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Tapia Rico G,Li M,Pavlakis N,Cehic G,Price TJ

    更新日期:2018-05-01 00:00:00

  • The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.

    abstract::With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

    更新日期:2002-08-01 00:00:00

  • A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

    abstract:BACKGROUND:We performed a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer to assess the effectiveness of this therapy. METHODS:We searched MEDLINE, The Cochrane Library, Science Citation Index, LILACS and SIGLE for randomi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Shelley MD,Kumar S,Wilt T,Staffurth J,Coles B,Mason MD

    更新日期:2009-02-01 00:00:00

  • Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

    abstract::In the last few years, several drugs targeting signalling proteins critical for melanoma entered clinical evaluation. In 2011 vemurafenib (Zelboraf®, F. Hoffman-La Roche Ltd.) was approved for BRAF V600-positive melanoma and showed high overall response rates (48-53%). However recent results from a phase II clinical t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Nijenhuis CM,Haanen JB,Schellens JH,Beijnen JH

    更新日期:2013-06-01 00:00:00

  • Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?

    abstract:BACKGROUND:Patients who are diagnosed with cancer want advice on how they may alter their diet or which diet supplements they should take to augment chemotherapy. METHODS:We conducted a review of the literature mostly from the last 15 years on the interaction between dietary constituents and antineoplastic therapy in ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: D'Incalci M,Steward WP,Gescher AJ

    更新日期:2007-05-01 00:00:00

  • Markers of bone turnover in prostate cancer.

    abstract::Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Garnero P

    更新日期:2001-06-01 00:00:00

  • Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment.

    abstract::This review summarizes emerging information regarding the Hedgehog (Hh) signaling pathway during neoplastic transformation in the gastrointestinal tract. Although there is a role for the well-established canonical pathway in which Hedgehog ligands interact with their receptor Patched, there is sufficient evidence that...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Merchant JL,Saqui-Salces M

    更新日期:2014-02-01 00:00:00

  • The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.

    abstract::We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Paukovits WR,Moser MH,Binder KA,Paukovits JB

    更新日期:1990-09-01 00:00:00

  • Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

    abstract:BACKGROUND:Treatment of relapsed hematological malignancies after an allogeneic peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) from the stem cell donor is an attractive clinical option to salvage this group of patients. METHODS:We reviewed the important studies looking at d...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Deol A,Lum LG

    更新日期:2010-11-01 00:00:00